The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...

Americans will soon have access to an infusion device that provides round-the-clock effective relief of Parkinson's disease.

The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...

Patients living with Parkinson’s disease are encouraged to engage in regular exercise to help manage symptoms and improve ...

People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.

Inhibikase’s setback continues biopharma’s losing streak against Parkinson’s, marked by several clinical failures and ...

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson's diseaseONAPGO is a wearable subcutaneous infusion devi ...

2024 — A research team examined the effect of Ecklonia cava polyphenols on the prevention of Parkinson's disease. It was found that the oral intake of the seaweed antioxidants restores motor ...

HighlightsTopline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February ...

2024 — A research team examined the effect of Ecklonia cava polyphenols on the prevention of Parkinson's disease. It was found that the oral intake of the seaweed antioxidants restores motor ...